Liquid passage device
The liquid passage device with multiple chambers and structured flow paths addresses uneven flow issues, improving cell function and preventing coagulation by ensuring uniform liquid contact with particles.
Patent Information
- Application Number
- PCT/JP2026/017328
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-01
- Publication Date
- 2026-11-12
AI Technical Summary
Conventional liquid passage devices experience uneven liquid flow due to the conventional method of filling particles, leading to inefficient cell function and potential coagulation of bodily fluids, particularly when using whole blood.
A liquid passage device with a flow path comprising multiple chambers for containing particles that hold cells, ensuring uniform liquid passage through a structured arrangement of chambers and flow paths.
The device enables uniform liquid flow, enhancing cell function and preventing coagulation, particularly when used with bodily fluids like blood, by ensuring all particles are evenly contacted by the liquid.
Smart Images

Figure JP2026017328_12112026_PF_FP_ABST
Abstract
Description
Liquid passage device
[0001] The present invention relates to a liquid passage device and the like.
[0002] In recent years, it has been reported that drug discovery screening for developing new pharmaceuticals using tissues and organs derived from pluripotent stem cells such as iPS / ES cells, and regenerative medicine that compensates for lost organ functions are being realized (Non-Patent Document 1, Patent Document 1). In relation to this, it has also recently been reported that a column containing alginate beads retaining liver organoids is used, the extracorporeal circuit including the column is connected to ACLF (acute-on-chronic liver failure) model rats and ALF (acute liver failure) model rats, and whole blood is circulated to attempt to alleviate liver failure symptoms.
[0003] A liquid passage column is packed with particles for the purpose of, for example, adsorbing specific components in a liquid. For example, Patent Document 1 describes disposing a column packed with adsorbent particles intended for adsorbing low-density lipoprotein and / or very-low-density lipoprotein in a body fluid in the circuit of a hemodialyzer.
[0004] Takebe, et al. Nature, 499: 481-484, 2013Reza, H.A., et al. Nature, 641: 1258-1267, 2025
[0005] JP 2022-79374 A
[0006] The inventors of this invention were conducting research to develop a liquid-passing device containing cells-retaining particles when they discovered that if the particles were "filled" into the device's channel in the conventional way and the liquid was passed through, the flow would become uneven. This problem leads to a decrease in the efficiency of the liquid's contact with the particles, preventing all the functions of the cells within the device (e.g., supplying substances secreted / released by the cells to the liquid, converting substances in the liquid through enzymatic action, etc.) from being fully performed. Furthermore, since there is a limit to the time that cells can maintain their function within the device, the above problem prevents the cells within the device from fully performing their functions within that limited time. Moreover, if bodily fluids (especially blood, and especially whole blood) are used as the liquid to be passed through, the above problem can lead to the coagulation of the bodily fluids within the device.
[0007] The present invention aims to provide a liquid passage device containing cells-holding particles, which allows for more uniform passage of the liquid.
[0008] In view of the above problems, the inventors diligently conducted research and found that the above problems can be solved if the liquid passage device has a liquid inlet and a liquid outlet, and the flow path A between the liquid inlet and the liquid outlet has a plurality of chambers for containing particles that hold cells. Based on this finding, the inventors furthered their research and completed the present invention. That is, the present invention encompasses the following embodiments.
[0009] Item 1. A liquid passage device comprising a liquid inlet and a liquid outlet, wherein the flow path A between the liquid inlet and the liquid outlet comprises a plurality of chambers for containing particles that hold cells.
[0010] Item 2. The liquid passage device according to Item 1, wherein the number of chambers is 10 to 50,000.
[0011] Item 3. A liquid passage device according to item 1 or 2, wherein each chamber is connected to an adjacent chamber by a flow path.
[0012] Item 4. A liquid passage device according to any one of items 1 to 3, wherein the number of particles contained in each chamber is 1 to 3.
[0013] Item 5. A liquid passage device according to any one of items 1 to 4, wherein the liquid is a liquid containing bodily fluids.
[0014] Item 6. The liquid passage device according to item 5, wherein the bodily fluid is blood.
[0015] Item 7. A liquid passage device according to any one of items 1 to 6, wherein the cells are a cell aggregate.
[0016] Item 8. The liquid passage device according to item 7, wherein the cell mass is a liver tissue mass.
[0017] Item 9. A liquid passage device according to any one of items 1 to 8, wherein the particles are polymer particles.
[0018] Item 10. A liquid passage device according to any one of items 1 to 9, wherein the flow path A comprises a flow path A1 including a plurality of chambers arranged in the direction from the liquid inlet to the liquid outlet.
[0019] Item 11. The liquid passage device according to item 10, comprising a plurality of the flow paths A1.
[0020] Item 12. The liquid passage device according to Item 11, wherein chambers are connected by a flow path between adjacent flow paths A1.
[0021] Item 13. A liquid passage device according to Item 12, wherein, within flow path A1, the minimum value X1 and maximum value X2 of the distance between any chamber and the nearest chamber satisfy the formula: 0.3 ≤ X1 / X2 ≤ 1, and the minimum value Y1 and maximum value Y2 of the distance between any chamber in any flow path A1 and the nearest chamber in the other flow path A1 satisfy the formula: 0.3 ≤ Y1 / Y2 ≤ 1.
[0022] According to the present invention, it is possible to provide a liquid passage device containing cells-holding particles, which allows the liquid to pass through more uniformly.
[0023] The test overview for Comparative Example 1 is shown. The results for Comparative Example 1 are shown. The shape and dimensions of the liquid passage column for Example 1 are shown. The shape and dimensions of the liquid passage column for Example 2 are shown. The fluid circuit system for Test Example 2 is shown. The overview of the column designed for Test Example 3 is shown. The results for Test Example 3 are shown. IMCA architecture and scalability. (a) Longitudinal repetition of a structured chamber pattern. (b) Multiple arrays arranged on a single plate by parallel arrangement in plane. (c) Vertical stacking of multiple flow path surfaces enables the formation of a compact and clinically scalable array (106 × 130 × 20 mm (length × width × height)). Simplified 3D model of IMCA. (a) Device housing showing the bead array with inlet / outlet and external dimensions (67 × 60 × 14.5 mm (length × width × height)). (b) Photograph of a 3D printed prototype (transparent resin). (a) Simplified 3-4-3 chamber-channel configuration with chamber numbers 1-6. Intermediate planes AA are used to integrate the cross-sectional flow rates (q3 and q4); similar intermediate planes are used for other cross-sections. (b) Fixed geometric parameters. (c) Geometric design variables and coordinates: chamber diameters D1-D4, channel diameters W13, W23, W24, and chamber center coordinates (X3, Z3) and (X4, Z4). Conceptual diagram of a multi-power MLP alternative model mapping the IMCA geometry to the FPI. (a) Geometry comparison of the original IMCA and (b) optimized IMCA. Axial intermediate plane velocity vectors, color-coded according to velocity magnitude, in the original and (b) optimized IMCA. The inset enclosed in a dotted circle is a magnified view of the chamber-channel region showing reduced bypass and recirculation near the walls in the optimized design. The color boundaries and vector scaling are identical in both panels. Fully primed IMCA before PIV measurement: (a) original, (b) optimized version. Intermediate surface velocity distribution obtained from PIV of (a) original and (b) optimized IMCA.(a) Comparison of contour lines of the absolute values of mid-plane velocity obtained from PIV for the original and (b) optimized IMCA, comparing (a) the velocity magnitude contour lines obtained from PIV and (b) the predicted contour lines obtained from CFD. For the optimized IMCA, comparison of (a) the velocity magnitude contour lines obtained from PIV and (b) the predicted contour lines obtained from CFD.
[0024] In this specification, the expressions “contains” and “includes” include the concepts of “contains,” “includes,” “substantially consists of,” and “consistes of only.”
[0025] In this specification, when specifying multiple upper and / or lower limits for a numerical range, even if not explicitly stated, the specification of a numerical range combining at least the maximum value of the upper limit and the minimum value of the lower limit is directly described, and all numerical ranges obtained by combining any upper limit from among the upper limits and any lower limit from among the lower limits are included in one embodiment of the present invention. Also, in this specification, a numerical range connected by "~" means a numerical range that includes the numbers before and after "~" as the lower and upper limits. When multiple lower limits and multiple upper limits are shown separately, any lower and upper limits can be selected and connected by "~".
[0026] In one embodiment, the present invention relates to a liquid passage device comprising a liquid inlet and a liquid outlet, wherein the flow path A between the liquid inlet and the liquid outlet comprises a plurality of chambers for containing particles that hold cells (which may be referred to as "the device of the present invention" in this specification).
[0027] A liquid passage device is not particularly limited as long as it comprises a liquid inlet (sometimes referred to as "inlet" in this specification), a liquid outlet (sometimes referred to as "outlet" in this specification), and a flow path A between the liquid inlet and the liquid outlet, and has a structure that allows liquid introduced from the liquid inlet to pass through the flow path A and be discharged from the liquid outlet.
[0028] The material for the liquid passage device is not particularly limited, as long as it is a material that can be molded to form a flow path with a chamber. Examples of materials include various resins, more specifically thermoplastic resins such as acrylic resin (PMMA), polyethylene, polypropylene, polyvinyl chloride, polyvinylidene chloride, polystyrene, polyvinyl acetate, polytetrafluoroethylene, ABS (acrylonitrile butadiene styrene) resin, AS (acrylonitrile styrene) resin, and fluororesins such as Teflon®; and thermosetting resins such as phenolic resin, epoxy resin, melamine resin, urea resin, unsaturated polyester resin, alkyd resin, polyurethane, thermosetting polyimide, and silicone rubber. Alternatively, metal may be used instead of resin.
[0029] The material may be a single type or a combination of two or more types.
[0030] In one embodiment of the present invention, it is preferable to use a material that is blood-compatible as the material. In another embodiment of the present invention, the surface that comes into contact with the liquid may also be coated. The coating material is not particularly limited, but examples include antithrombotic materials.
[0031] The liquid inlet and liquid outlet are typically located at the ends of the device of the present invention. As shown in Figures 3 and 4, the liquid inlet is typically located at one end of the device of the present invention, and the liquid outlet is located at the other end opposite the liquid inlet.
[0032] The shape of the liquid inlet and liquid outlet is not particularly limited as long as it is a shape that allows for the introduction / discharge of liquid. Preferably, these outlets can be cylindrical protrusions, as shown in Figures 3 and 4, for example, to facilitate the attachment of tubes.
[0033] The number of liquid inlets and liquid outlets is usually one, but in one embodiment of the present invention, there can be multiple, for example, 2 to 200, 4 or more, 8 or more, 12 or more, 20 or more, 30 or more, 40 or more, 50 or more, 100 or more, 150 or less, 120 or less, 100 or less, 80 or less, 60 or less, 50 or less, 40 or less, 30 or less, or 20 or less.
[0034] Flow path A refers to the entire flow path between the liquid inlet and the liquid outlet. Even if the flow path branches from the liquid inlet, all of those branched flow paths are considered to be flow path A. In one embodiment of the present invention, flow path A includes a plurality of flow paths extending in the direction from the liquid inlet to the liquid outlet. The number of such flow paths can be, for example, 1 to 200, 2 or more, 4 or more, 8 or more, 12 or more, 20 or more, 30 or more, 40 or more, 50 or more, 100 or more, 150 or less, 120 or less, 100 or less, 80 or less, 60 or less, 50 or less, 40 or less, 30 or less, or 20 or less. Furthermore, the shape of flow path A is not particularly limited and may be, for example, tubular or flattened. Also, all of the plurality of chambers may be connected to each other via one flow path.
[0035] Channel A comprises multiple chambers that contain particles that hold cells.
[0036] The cells are not particularly limited as long as they are living cells, but are typically animal cells. Examples of cells include hepatocytes, kidney cells, peritoneal cells, lung cells, nerve cells, glial cells, blood cells, hematopoietic stem cells / progenitor cells, gametes (sperm, egg cells), fibroblasts, epithelial cells, vascular endothelial cells, keratin-producing cells, muscle cells, epidermal cells, endocrine cells, ES cells, iPS cells, tissue stem cells, cancer cells, etc. In a preferred embodiment of the present invention, the cells are hepatocytes. The hepatocytes are not particularly limited as long as they are cells that make up the liver, and examples include hepatic parenchymal cells, hepatic sinusoidal endothelial cells, Kupffer cells, hepatic stellate cells, pit cells, bile duct epithelial cells, mesothelial cells, etc.
[0037] The cells may be individual cells or in a cell aggregate. In a preferred embodiment of the present invention, the cells are in a cell aggregate to more effectively perform their functions. The cell aggregate can be a tissue aggregate (which can also be called an organoid), and in a preferred embodiment of the present invention, it is a liver tissue aggregate.
[0038] The size of the cell / tissue aggregate is not particularly limited, but in one embodiment, the longest axis is, for example, 10–5000 μm, 30–2000 μm, 50–1000 μm, or 70–500 μm.
[0039] The cells held by one particle may be of a single type alone, or may be a combination of two or more types.
[0040] The particles hold cells. The cells may be present inside the particles, or may be present on the particle surfaces. The number of cells held by the particles is not particularly limited. In one aspect of the present invention, the number of cell masses / tissue masses held by the particles is, for example, 1 to 2000, 5 to 1500, 10 to 1000, 20 to 500, or 50 to 300 per particle.
[0041] The shape of the particles is not particularly limited, but from the viewpoint of not disturbing the flow of liquid, the shape is preferably spherical (for example, a perfect sphere, an ellipsoid).
[0042] The material constituting the particles is not particularly limited as long as it can hold cells. The material can be, for example, a polymer. As the polymer, polysaccharides are preferable from the viewpoint of safety to living bodies. Examples of the polysaccharides include alginic acid, agarose, carrageenan, pectin, gellan gum, xanthan gum, locust bean gum, tamarind seed gum, curdlan and the like.
[0043] The method for producing the particles holding cells is not particularly limited. The particles can be obtained, for example, by solidifying a cell suspension containing a polymer and cells so as to form the target particle shape. In a more specific example, when alginic acid is used, a cell suspension containing alginic acid and cells is added dropwise to a cation solution (for example, a solution containing calcium ions), whereby the droplets introduced into the cation solution solidify to form particles.
[0044] The size of the particles is not particularly limited as long as the particles can be kept accommodated in the chamber in the liquid passing state, and can be appropriately designed according to the size of the chamber, the size of the flow path between the chambers, and the structures thereof. In a preferred aspect, the major axis of the particles is 0.5 to 20 mm, further 0.7 to 10 mm, further 1 to 5 mm, and further 1.5 to 4.5 mm.
[0045] The chamber accommodates particles. The number of particles accommodated in the chamber is not particularly limited, but is preferably smaller from the viewpoint of the uniformity of the liquid flow. The smaller the number of particles accommodated in the chamber, the less likely the problem (flow bias) of conventional devices packed with a large number of particles occurs. The number of particles per chamber is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, still more preferably 1 to 2, and particularly preferably 1.
[0046] The shape of the particles is not particularly limited, but from the viewpoint of not disturbing the liquid flow, it is preferably spherical (for example, a true sphere, an ellipsoid).
[0047] The size of the chamber is not particularly limited, and is not particularly limited as long as the state where the particles are accommodated in the chamber can be maintained during the liquid passing state, and can be appropriately designed according to the size of the particles, the size of the flow path between the chambers, and these structures. In a preferred embodiment, the major diameter of the chamber is 0.5 to 20 mm, further 0.7 to 10 mm, further 1 to 7 mm, further 1 to 5 mm, and further 1.5 to 4.5 mm.
[0048] The spatial volume of the chamber can be, relative to 100% of the volume of the accommodated particles (when a plurality of particles are accommodated, the total volume of the plurality of particles), preferably more than 100% and 500% or less, more than 100% and 300% or less, more than 100% and 200% or less, more than 100% and 150% or less, more than 105% and 150% or less, or more than 110% and 130% or less. By making the spatial volume of the chamber closer to the volume of the accommodated particles, disturbance of the liquid flow caused by the movement of the particles in the chamber can be suppressed. In addition, the spatial volume of the device of the present invention can be made smaller, whereby the circulation amount when circulating a biological body fluid in a circuit including the device of the present invention can be made smaller, and the burden on the living body (the burden due to reduced body fluid) can be reduced.
[0049] The ratio (minimum / maximum) of the minimum spatial volume of the chambers in the device of the present invention to the maximum spatial volume is preferably 0.3 to 1, more preferably 0.5 to 1, even more preferably 0.7 to 1, even more preferably 0.8 to 1, particularly preferably 0.9 to 1, particularly more preferably 0.95 to 1, and especially preferably 1. When this ratio is 1, all chambers are the same size, as shown in Figures 3 and 4.
[0050] Flow path A is equipped with multiple chambers. This suppresses flow bias compared to filling all the particles contained in the multiple chambers into a single space, making it possible to bring more particles into contact with the liquid more uniformly.
[0051] The number of chambers is not particularly limited, but in one embodiment, it can be calculated based on the required number of cells set according to the application of the device of the present invention, the number of cells per particle, and the number of particles in one chamber. The number of chambers can be, for example, 2 to 50,000, 5 to 50,000, 10 to 50,000, 10 to 10,000, 10 to 5,000, 50 to 5,000, 100 to 5,000, 200 to 5,000, 500 to 5,000, 1,000 to 5,000, or 1,000 to 4,000, and can also be 3,000 or less, 2,000 or less, 1,000 or less, 500 or less, or 300 or less.
[0052] In the device of the present invention, it is preferable that each chamber is connected to adjacent chambers (particularly preferably all adjacent chambers) by a flow path. This allows the liquid to pass through more uniformly.
[0053] The length (distance between chambers) and diameter (major or minor diameter) of the flow path connecting the chambers are preferably smaller. This reduces the amount of bodily fluids circulated when circulating them through the circuit containing the device of the present invention, thereby reducing the burden on the body (burden of fluid loss). The length and diameter are preferably 5 mm or less, more preferably 4 mm or less, even more preferably 3 mm or less, and even more preferably 2 mm or less, respectively. These lower limits are not particularly limited and may be, for example, 0.1 mm or more, 0.2 mm or more, 0.5 mm or more, or 0.7 mm or more.
[0054] The ratio (minimum / maximum) of the minimum length of the flow path connecting the chambers (distance between chambers) to the maximum length of said length is preferably 0.3 to 1, more preferably 0.5 to 1, even more preferably 0.7 to 1, even more preferably 0.8 to 1, particularly preferably 0.9 to 1, particularly more preferably 0.95 to 1, and especially preferably 1. When this ratio is 1, the lengths of the flow paths connecting the chambers are all the same, as shown in Figures 3 and 4.
[0055] The ratio (minimum / maximum) of the minimum diameter (major or minor diameter) of the flow path connecting the chambers to the maximum diameter is preferably 0.3 to 1, more preferably 0.5 to 1, even more preferably 0.7 to 1, even more preferably 0.8 to 1, particularly preferably 0.9 to 1, particularly more preferably 0.95 to 1, and especially preferably 1. When this ratio is 1, the diameters of the flow paths connecting the chambers are all the same, as shown in Figures 3 and 4.
[0056] The flow path A preferably comprises a flow path A1 including a plurality of chambers arranged in the direction from the liquid inlet to the liquid outlet. In the chamber arrangement in Figures 3 and 4, the flow path A1 corresponds to a series of flow paths. In Figure 3, there are 5 flow paths A1, and in Figure 4, there are 27 flow paths A1 (9 flow paths A1 per layer × 3 layers).
[0057] The number of chambers contained in one flow path A1 is, for example, 2 or more, 3 or more, 5 or more, 7 or more, 10 or more, 15 or more, 20 or more, 30 or more, 40 or more, or 50 or more, and also, for example, 100 or less, 70 or less, 50 or less, 40 or less, 30 or less, 20 or less, or 10 or less.
[0058] The device of the present invention preferably comprises a plurality of flow paths A1. The number of flow paths A1 may be, for example, 2 or more, 3 or more, 5 or more, 7 or more, 10 or more, 15 or more, 20 or more, 30 or more, 40 or more, 50 or more, 70 or more, 100 or more, 150 or more, or 200 or more, and may also be, for example, 1000 or less, 500 or less, 300 or less, 200 or less, 150 or less, 100 or less, 70 or less, 50 or less, 40 or less, 30 or less, 20 or less, or 10 or less.
[0059] In the device of the present invention, it is preferable that chambers are connected by a flow path between adjacent flow paths A1. In other words, it is preferable that a chamber in one flow path A1 is connected to a chamber in another flow path A1 adjacent to that flow path A1 by a flow path.
[0060] In the device of the present invention, it is preferable that, within flow path A1, the minimum value X1 and maximum value X2 of the distance between any chamber and the nearest chamber thereto satisfy the formula X: 0.3 (more preferably 0.5, even more preferably 0.7, even more preferably 0.8, particularly preferably 0.9, particularly more preferably 0.95, especially preferably 1) ≤ X1 / X2 ≤ 1, and / or (preferably, "and") the minimum value Y1 and maximum value Y2 of the distance between any chamber in any flow path A1 and the nearest chamber in the other flow path A1 satisfy the formula Y: 0.3 (more preferably 0.5, even more preferably 0.7, even more preferably 0.8, particularly preferably 0.9, particularly more preferably 0.95, especially preferably 1) ≤ Y1 / Y2 ≤ 1.
[0061] Equation X specifies that the chambers are arranged in the flow path A1 so that they are more evenly spaced. When X1 / X2 is 1, the chambers are perfectly evenly spaced in the flow path A1, as shown in Figures 3 and 4.
[0062] In other words, the definitions of Y1 and Y2 are the minimum and maximum values of the distance between any chamber (chamber A11) in any flow path A1 (flow path A11) and the nearest chamber (chamber A12) in another flow path A1 (flow path A12: usually a flow path A1 adjacent to flow path A11) (the distance between chamber A11 and chamber A12).
[0063] Equation Y assumes that the channels A1 are arranged such that the chamber at one end of channel A11 and the chamber at one end of channel A12 are closer together, and that the channels A1 are spaced more evenly apart. When Y1 / Y2 is 1, as shown in Figures 3 and 4, the channels A1 are arranged at equal intervals without any displacement in the direction of the channels.
[0064] When the device of the present invention has a plurality of flow paths A1, from the viewpoint of uniformity of flow velocity and / or flow rate among the plurality of flow paths A1, it is preferable that the major axis (P1) of the chamber in the outermost flow path A1 is longer than the major axis (P2) of the chamber in the central flow path A1. P1 / P2 is, for example, 1.05 to 1.50, preferably 1.10 to 1.40, more preferably 1.15 to 1.35, and even more preferably 1.20 to 1.30.
[0065] When the device of the present invention has a plurality of flow paths A1, from the viewpoint of uniformity of flow velocity and / or flow rate among the plurality of flow paths A1, it is preferable that the diameter of the flow path connecting the chambers in the outermost flow path A1 (Q1) is longer than the diameter of the flow path connecting the chambers in the central flow path A1 (Q2). Q1 / Q2 is, for example, 1.05 to 2.00, preferably 1.20 to 1.80, more preferably 1.30 to 1.70, even more preferably 1.40 to 1.65, and even more preferably 1.50 to 1.60.
[0066] The liquid through which the device of the present invention passes is not particularly limited. By passing a liquid through the device of the present invention, the liquid comes into contact with particles that hold cells, so that substances secreted / released from cells can be supplied to the liquid, and / or substances in the liquid can be adsorbed onto the particles and / or converted by enzymatic action. The design of the device can be appropriately adjusted according to the properties of the liquid (e.g., viscosity, flow rate, etc.).
[0067] The liquid is preferably a liquid containing body fluids. While there are no particular limitations on body fluids, examples include blood, saliva, cerebrospinal fluid, synovial fluid, urine, tissue fluid, sweat, tears, etc. Among these, blood is particularly preferred. Examples of blood include whole blood, serum, and plasma, with whole blood being particularly preferred. Furthermore, the body fluid is not limited to blood, but preferably a body fluid containing cellular (preferably blood cell) components.
[0068] When the liquid contains body fluids, the body fluid content relative to 100% by mass of the liquid is preferably 50% by mass or more, more preferably 70% by mass or more, even more preferably 80% by mass or more, even more preferably 90% by mass or more, particularly preferably 95% by mass or more, and especially preferably 98% by mass or more.
[0069] The device of the present invention may contain particles other than the "cell-retaining particles" (other particles). These other particles may be contained in a chamber containing the "cell-retaining particles," or in other chambers. In the former case, the other particles may be positioned in the chamber closer to the liquid inlet than, for example, the "cell-retaining particles." In the latter case, the other chamber may be positioned even closer to the liquid inlet than the chamber closest to the liquid inlet among the chambers containing the "cell-retaining particles." As materials for the other particles, cellulose derivatives such as methylcellulose and cellulose acetate can be used. In one embodiment of the present invention, when the cells of the "cell-retaining particles" are created by the method shown in Non-Patent Document 2, they are arranged in the order of Zone 1, Zone 2, and Zone 3 from the liquid inlet chamber toward the liquid outlet.
[0070] In one embodiment, the device of the present invention can constitute a part of a circuit in which bodily fluids circulate, connected to a living organism (specifically, a bodily fluid circulation circuit such as hemodialysis). By using hepatocytes in the device of the present invention to circulate the blood of the living organism through the above circuit, it becomes possible to substitute for or supplement liver function, for example. Furthermore, the device of the present invention can be used as, for example, an implantable device. In this case, for example, the device of the present invention can be placed in a bodily fluid circulation circuit or a region containing bodily fluids within the living organism. The device of the present invention can also be used in drug discovery research. In this case, for example, a liquid containing a test substance can be passed through the device of the present invention, and the behavior, dynamics, and response of cells in the device of the present invention can be examined to evaluate the drug performance of the test substance.
[0071] The present invention will be described in detail below based on examples, but the present invention is not limited to these examples.
[0072] Reference Example 1 Alginate calcium beads for holding liver tissue aggregates were prepared as follows. The liver tissue aggregates were prepared from iPS cells according to the usual method for preparing liver organoids. Alginate aqueous solution in which liver tissue aggregates were suspended (liver tissue aggregate concentration: 10 9 One drop of alginate (1.5% w / v g / mL, 1.5% w / v g / mL) was added to an aqueous calcium chloride solution (composition: 10 mM HEPES, 154 mM NaCl, 115 mM CaCl2). The resulting beads were used as cell-holding particles in Test Example 2.
[0073] Comparative Example 1 A column containing a channel consisting of a single space measuring 25 mm vertically and 15 mm horizontally was fabricated using a 3D printer, and simulated beads (material: acrylic, diameter 4 mm) were packed into the channel as shown in Figure 1 to obtain a column for liquid passage.
[0074] Test Example 1: The test overview is shown in Figure 1. A PVC tube and syringe were connected in that order to the inlet of the liquid passage column of Comparative Example 1, and a PVC tube was connected to the outlet. Using the syringe, a liquid consisting of tap water containing fluorescent tracers (polymer particles, φ6 μm) was introduced and passed through the outlet of the column. At the same time, laser light (wavelength: 532 nm) was irradiated onto the column to visualize the fluorescent tracers, thereby visualizing the flow of the liquid passing through the channel. In addition, the migration speed of each fluorescent tracer was measured based on image analysis.
[0075] The results are shown in Figure 2. There was a bias in the flow within the column (fluorescence tracer distribution), and the flow velocity (movement speed of the fluorescence tracer) also differed significantly depending on the position within the column. Furthermore, there were areas where the liquid flow was not only from inlet to outlet (forward flow), but also in the opposite direction (backward flow).
[0076] Example 1 A liquid-passing column (Figure 3) was fabricated using acrylic resin as the material, with a flow path between the inlet and outlet comprising 23 chambers containing cell-holding particles. Each chamber contained one bead (cell-holding particle: 2 mm in diameter).
[0077] Example 2 A liquid-passing column (Figure 4) was fabricated using acrylic resin as the material, with a flow path between the inlet and outlet comprising 230 chambers containing cell-holding particles. Each chamber contained one bead (cell-holding particle: 2 mm in diameter).
[0078] Test Example 2 A fluid circuit system was constructed using the liquid passage column from Example 1 as shown in Figure 5. Blood was introduced from a syringe pump at a set flow rate of 0.5 mL / min. As a result, the column perfusion time was 2 min. From this, the amount of blood in the column was calculated to be 1 mL. After blood perfusion, the column was washed, and blood staining was observed on all the beads. This suggests that the blood came into contact with all the beads relatively evenly.
[0079] In Test Example 3, as shown in Figure 6, a random column (a column with the same structure as Comparative Example 1) and an aligned column (a column with the same structure as Example 2) were designed. The diameter of the spherical beads contained in the chamber ("capsule" in Figure 6) was 2 mm, and the pressure boundary conditions were: inlet pressure: 5 kPa, outlet pressure: 0 kPa, and the working fluid was blood (1060 kg / m³). 3 Under the conditions of a non-Newtonian Carreau fluid model, the fluid velocity in the column was calculated using the finite element method with analysis software (ANSYS Fluent).
[0080] The results are shown in Figure 7. The random column showed uneven flow (low flow velocity inside the column), while the aligned column showed uniform flow in all beads.
[0081] In Test Example 4, the flow path design of an interconnected microchamber array (IMCA) used as a liquid passage column was optimized using computational science, and its behavior was analyzed by actually flowing liquid through the optimized IMCA. Details are described below.
[0082] Figures 8–11: The IMCA architecture was defined and parameterized as a scalable chamber-channel array with one bead per spherical chamber, distributing flow through a branching and merging network. This architecture features a clear scalability strategy through longitudinal iteration, in-plane parallelization, and vertical stacking. A consistent computational fluid dynamics (CFD) framework (including steady laminar flow and gravity; standardized mesh, numerical computation, and convergence) and a set of FPIs were established to quantify fluid distribution (cross-sectional flow rate and chamber contrast), viscous pressure loss excluding hydrostatic pressure, and shear index. To enable high-dimensional exploration, feasibility screening, automated CFD labeling (5,000 cases), and a machine learning-enhanced CFD workflow with multi-power MLP surrogates were implemented. This demonstrated near 100% predictive accuracy for key FPIs and confirmed data sufficiency plateau behavior. This behavior justifies the final dataset size for reliable surrogate-assisted optimization.
[0083] Figures 12–13: CFD comparisons showed that the baseline of the simplified cylindrical column exhibited significant spatial distribution bias, despite modest overall hydraulic / shear indices, due to recirculation by the inlet jet and bypass passages near the walls. The original IMCA reduced bypass compared to the baseline but still showed significant chamber-level distribution bias, and the parametric map showed that adjusting only the chamber diameter would not restore 1 for the most biased pair in the center of the chambers within the viable region. The IMCA optimized by difference equation (DE) analysis using a surrogate model, after CFD validation, achieved a chamber pair ratio of nearly 1. This represents a 93.8% improvement in mean deviation. Furthermore, robustness analysis showed that the optimized design maintained nearly uniform in-chamber flow even under realistic bead expansion and axial displacement.
[0084] Figures 14–18: Time-resolved 2D2C particle image velocimetry (PIV) at the xz mid-plane in the transparent acrylic model provided experimental evidence that IMCA guides flow through the chamber-channel network and suppresses the prominent peripheral bypass phenomenon characteristic of conventional packed structures. In both the original and optimized geometry, PIV reproduced the primary channel topology and the location of the channel-specific velocity peaks predicted by CFD, supporting the computational interpretation of how this structure forms the channels. In the optimized IMCA, the degree of agreement was spatially non-uniform. The right-hand peak matched well, but the left-hand and central peaks were underestimated in PIV. This is most likely due to reduced tracer visibility and compromised correlation robustness caused by the reduced transmittance of the acrylic and the entry of the laser sheet on the right. Comparisons between array regions and line integral results for lines 3–5 further supported the channel division consistent with CFD and showed that the sum of the inflow balance in pair 3–4 in the center of the chamber was considerably closer to uniformity in the optimized design than in the original design. Overall, this experiment provided qualitative and semi-quantitative validation of CFD-based comparisons used to evaluate and interpret the flow behavior of IMCA.
[0085] As shown in Figure 12, in the optimized IMCA, the major axis (P1) of the chamber in the outermost channel A1 was longer than the major axis (P2) of the chamber in the central channel A1, and the diameter (Q1) of the channel connecting the chambers in the outermost channel A1 was longer than the diameter (Q2) of the channel connecting the chambers in the central channel A1.
Claims
1. A liquid passage device comprising a liquid inlet and a liquid outlet, wherein the flow path A between the liquid inlet and the liquid outlet comprises a plurality of chambers for containing particles that hold cells.
2. The liquid passage device according to claim 1, wherein the number of chambers is 10 to 50,000.
3. The liquid passage device according to claim 1, wherein each chamber is connected to an adjacent chamber by a flow path.
4. The liquid passage device according to claim 1, wherein the number of particles contained in each chamber is 1 to 3.
5. The liquid passage device according to claim 1, wherein the liquid is a liquid containing bodily fluids.
6. The liquid passage device according to claim 5, wherein the bodily fluid is blood.
7. The liquid passage device according to claim 1, wherein the cells are a cell aggregate.
8. The liquid passage device according to claim 7, wherein the cell mass is a liver tissue mass.
9. The liquid passage device according to claim 1, wherein the particles are polymer particles.
10. The liquid passage device according to any one of claims 1 to 9, wherein the passage A comprises a passage A1 including a plurality of chambers arranged in the direction from the liquid inlet to the liquid outlet.
11. The liquid passage device according to claim 10, comprising a plurality of the flow paths A1.
12. The liquid passage device according to claim 11, wherein chambers are connected by a passage between adjacent passages A1.
13. A liquid passage device according to claim 12, wherein in flow path A1, the minimum value X1 and maximum value X2 of the distance between any chamber and the nearest chamber satisfy the formula: 0.3 ≤ X1 / X2 ≤ 1, and the minimum value Y1 and maximum value Y2 of the distance between any chamber in any flow path A1 and the nearest chamber in the other flow path A1 satisfy the formula: 0.3 ≤ Y1 / Y2 ≤ 1.
